3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test. 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological conditions, according to a new study that analyzed cryopreserved CSF samples ...
A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...
SEATTLE — Molecular testing has been widely integrated into mainstream healthcare, and its use is increasing in dermatology. It can help differentiate between skin conditions, for example, as some ...
Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...
NCCN now endorses CSF-based profiling for biopsy-infeasible HGG/GBM to enable molecular characterization required for ...
A new perspective paper explores the current state and future directions of precision medicine in colorectal cancer (CRC). It outlines advancements in molecular testing and their implications for ...
Endometrial cancer (EC) is the most common gynecologic malignancy in the United States, with an estimated incidence of 67,880 cases in 2024 1. Despite advances in diagnostics and therapeutics, the ...
During the COVID-19 health emergency, two strategies for detecting coronavirus infections were commonly adopted around the world. Part of Nature Outlook: Medical diagnostics Initially, in countries ...
Brain tumors have long forced pathologists into a difficult balancing act. Under the microscope, many look alike at first ...
A phase II trial of pembrolizumab plus olaparib for the treatment of patients with persistent/recurrent endometrial cancers. E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) ...
Development of custom amplicon-based test systems for detecting KRAS, NRAS, and BRAF gene mutations in colorectal cancer using next-generation sequencing (NGS). This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results